

# Sun Young Rha

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3598679/publications.pdf>

Version: 2024-02-01

395  
papers

14,797  
citations

31902

53  
h-index

28224

105  
g-index

400  
all docs

400  
docs citations

400  
times ranked

20702  
citing authors

#	ARTICLE	IF	CITATIONS
1	Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 3968-3976.	0.8	1,003
2	Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. <i>Lancet</i> , The, 2016, 387, 1629-1637.	6.3	610
3	A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. <i>Gut</i> , 2012, 61, 673-684.	6.1	562
4	Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. <i>Nature Genetics</i> , 2012, 44, 570-574.	9.4	560
5	Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 108, 241-250.	1.1	472
6	Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology</i> , 2014, 66, 704-710.	0.9	382
7	Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 2765-2772.	0.8	355
8	Oncogenic Pathway Combinations Predict Clinical Prognosis in Gastric Cancer. <i>PLoS Genetics</i> , 2009, 5, e1000676.	1.5	354
9	Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict Survival and Respond Differently to Chemotherapy. <i>Gastroenterology</i> , 2011, 141, 476-485.e11.	0.6	304
10	Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 286-296.	5.1	239
11	Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1637-1651.	5.1	233
12	Whole genome analysis for liver metastasis gene signatures in colorectal cancer. <i>International Journal of Cancer</i> , 2007, 121, 2005-2012.	2.3	203
13	Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. <i>Gut</i> , 2015, 64, 1721-1731.	6.1	197
14	Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2728-2735.	0.8	183
15	Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival and Cigarette Smoking Dosage in Patients With Resected Squamous Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 731-737.	0.8	154
16	PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2903-2913.	0.8	154
17	Caregiving burden and the quality of life of family caregivers of cancer patients: the relationship and correlates. <i>European Journal of Oncology Nursing</i> , 2015, 19, 376-382.	0.9	144
18	Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. <i>Cancer</i> , 2012, 118, 729-739.	2.0	132

#	ARTICLE	IF	CITATIONS
19	Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. <i>BMC Cancer</i> , 2016, 16, 434.	1.1	124
20	Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity. <i>Nature Communications</i> , 2016, 7, 12983.	5.8	123
21	Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma. <i>Annals of Surgery</i> , 2017, 265, 946-953.	2.1	117
22	A randomized phase II trial of S-1-oxaliplatin versus capecitabine+oxaliplatin in advanced gastric cancer. <i>European Journal of Cancer</i> , 2012, 48, 518-526.	1.3	116
23	Tumor perfusion-related parameter of diffusion-weighted magnetic resonance imaging: Correlation with histological microvessel density. <i>Magnetic Resonance in Medicine</i> , 2014, 71, 1554-1558.	1.9	115
24	Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells. <i>BMC Genomics</i> , 2012, 13, 348.	1.2	114
25	A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 5981-5992.	3.2	107
26	SNPAnalyzer 2.0: A web-based integrated workbench for linkage disequilibrium analysis and association analysis. <i>BMC Bioinformatics</i> , 2008, 9, 290.	1.2	106
27	Inhibition of Gastric Cancer Invasion and Metastasis by <i>PLA2G2A</i> , a Novel $\beta$ -Catenin/TCF Target Gene. <i>Cancer Research</i> , 2008, 68, 4277-4286.	0.4	103
28	Role of $^{18}$ F-Fluorodeoxyglucose Positron Emission Tomography in Detecting Extrahepatic Metastasis in Pretreatment Staging of Hepatocellular Carcinoma. <i>Oncology</i> , 2007, 72, 104-110.	0.9	101
29	Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population. <i>Gut</i> , 2021, 70, 829-837.	6.1	94
30	Prevalence and prognostic implications of psychological distress in patients with gastric cancer. <i>BMC Cancer</i> , 2017, 17, 283.	1.1	93
31	OPCML Is a Broad Tumor Suppressor for Multiple Carcinomas and Lymphomas with Frequently Epigenetic Inactivation. <i>PLoS ONE</i> , 2008, 3, e2990.	1.1	92
32	Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2015, 18, 824-832.	2.7	91
33	Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: A 15-year experience at a single institute. <i>Journal of Surgical Oncology</i> , 2007, 95, 461-468.	0.8	89
34	Integrated epigenomics identifies <i>BMP4</i> as a modulator of cisplatin sensitivity in gastric cancer. <i>Gut</i> , 2013, 62, 22-33.	6.1	88
35	EORTC-1203-GITCG - the aEINNOVATIONaE-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. <i>BMC Cancer</i> , 2019, 19, 494.	1.1	86
36	Activation of Hypoxia-Inducible Factor-1 $\alpha$ Is Necessary for Lysophosphatidic Acid-Induced Vascular Endothelial Growth Factor Expression. <i>Clinical Cancer Research</i> , 2006, 12, 6351-6358.	3.2	85

#	ARTICLE	IF	CITATIONS
37	Prediction of Recurrence of Early Gastric Cancer After Curative Resection. <i>Annals of Surgical Oncology</i> , 2009, 16, 1896-1902.	0.7	84
38	An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. <i>European Journal of Cancer</i> , 2012, 48, 324-332.	1.3	84
39	Brain metastases from colorectal carcinoma: prognostic factors and outcome. <i>Journal of Neuro-Oncology</i> , 2011, 101, 49-55.	1.4	81
40	Increased Expression of Matrix Metalloproteinase 9 Correlates with Poor Prognostic Variables in Renal Cell Carcinoma. <i>European Urology</i> , 2003, 44, 560-566.	0.9	77
41	Changing Patterns of Prognosticators During 15-Year Follow-Up of Advanced Gastric Cancer after Radical Gastrectomy and Adjuvant Chemotherapy: A 15-Year Follow-Up Study at a Single Korean Institute. <i>Annals of Surgical Oncology</i> , 2007, 14, 2730-2737.	0.7	72
42	Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial. <i>Annals of Surgical Oncology</i> , 2018, 25, 3222-3230.	0.7	69
43	Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. , 2019, 7, 30.		68
44	Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 663-669.	2.9	66
45	Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function. , 2019, 7, 339.		65
46	Cross-species chromatin interactions drive transcriptional rewiring in Epstein-Barr virus-positive gastric adenocarcinoma. <i>Nature Genetics</i> , 2020, 52, 919-930.	9.4	65
47	Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. <i>Cancer Letters</i> , 2004, 214, 215-224.	3.2	63
48	Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2005, 90, 215-221.	1.1	63
49	Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea. <i>Cancer Research and Treatment</i> , 2009, 41, 67.	1.3	63
50	A comparative study of volumetric analysis, histopathologic downstaging, and tumor regression grade in evaluating tumor response in locally advanced rectal cancer following preoperative chemoradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 204-210.	0.4	60
51	The Metalloprotease ADAMTS8 Displays Antitumor Properties through Antagonizing EGFR-MEK-ERK Signaling and Is Silenced in Carcinomas by CpG Methylation. <i>Molecular Cancer Research</i> , 2014, 12, 228-238.	1.5	58
52	Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. <i>BMC Cancer</i> , 2015, 15, 154.	1.1	58
53	Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 825-835.	1.1	57
54	Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy. <i>Annals of Surgery</i> , 2016, 263, 96-102.	2.1	56

#	ARTICLE	IF	CITATIONS
55	Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 2418-2426.	0.8	55
56	Identification of genes with correlated patterns of variations in DNA copy number and gene expression level in gastric cancer. <i>Genomics</i> , 2007, 89, 451-459.	1.3	54
57	<i>CD44-SLC1A2</i> Gene Fusions in Gastric Cancer. <i>Science Translational Medicine</i> , 2011, 3, 77ra30.	5.8	54
58	Intermediate Dose 5-Fluorouracil-Induced Encephalopathy. <i>Japanese Journal of Clinical Oncology</i> , 2006, 36, 55-59.	0.6	53
59	Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 429-438.	0.7	52
60	The effect of spleen-preserving lymphadenectomy on surgical outcomes of locally advanced proximal gastric cancer. <i>Journal of Surgical Oncology</i> , 2009, 99, 275-280.	0.8	52
61	Early Tumor Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer. <i>Cancer Discovery</i> , 2022, 12, 984-1001.	7.7	52
62	Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1002-1011.	0.3	51
63	Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference. <i>Gastric Cancer</i> , 2016, 19, 15-20.	2.7	51
64	Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy. <i>BMC Cancer</i> , 2018, 18, 1116.	1.1	51
65	Proper Timing of Adjuvant Chemotherapy Affects Survival in Patients with Stage 2 and 3 Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 224-231.	0.7	50
66	Kidney Cancer Working Group Report. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, i51-i56.	0.6	49
67	An Association Between RRM1 Haplotype and Gemcitabine-Induced Neutropenia in Breast Cancer Patients. <i>Oncologist</i> , 2007, 12, 622-630.	1.9	48
68	Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 55-63.	1.1	48
69	Sunitinib for Asian Patients with Advanced Renal Cell Carcinoma: A Comparable Efficacy with Different Toxicity Profiles. <i>Oncology</i> , 2011, 80, 395-405.	0.9	48
70	Patterns of regional recurrence after curative D2 resection for stage III (N3) gastric cancer: Implications for postoperative radiotherapy. <i>Radiotherapy and Oncology</i> , 2012, 104, 367-373.	0.3	48
71	Caregiving burden and health-promoting behaviors among the family caregivers of cancer patients. <i>European Journal of Oncology Nursing</i> , 2015, 19, 174-181.	0.9	48
72	Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma. <i>Cancer Discovery</i> , 2017, 7, 630-651.	7.7	48

#	ARTICLE	IF	CITATIONS
73	The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. <i>Targeted Oncology</i> , 2013, 8, 203-209.	1.7	47
74	Characterization of naturally Epstein-Barr virus-infected gastric carcinoma cell line YCCEL1. <i>Journal of General Virology</i> , 2013, 94, 497-506.	1.3	47
75	Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. <i>Oncotarget</i> , 2016, 7, 44608-44620.	0.8	46
76	Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients. <i>BMC Cancer</i> , 2016, 16, 385.	1.1	46
77	Rab25 augments cancer cell invasiveness through a $\beta$ 1 integrin/EGFR/VEGF-A/Snail signaling axis and expression of fascin. <i>Experimental and Molecular Medicine</i> , 2018, 50, e435-e435.	3.2	45
78	PRL3-zumab, a first-in-class humanized antibody for cancer therapy. <i>JCI Insight</i> , 2016, 1, e87607.	2.3	44
79	The Clinical Outcome of Chemotherapy-Induced Amenorrhea in Premenopausal Young Patients with Breast Cancer with Long-Term Follow-up. <i>Annals of Surgical Oncology</i> , 2010, 17, 3259-3268.	0.7	43
80	Symptom clusters during palliative chemotherapy and their influence on functioning and quality of life. <i>Supportive Care in Cancer</i> , 2017, 25, 1519-1527.	1.0	43
81	Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma. <i>International Journal of Hyperthermia</i> , 2010, 26, 305-315.	1.1	42
82	A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy. <i>Cancer</i> , 2011, 117, 2050-2057.	2.0	42
83	A Densely Interconnected Genome-Wide Network of MicroRNAs and Oncogenic Pathways Revealed Using Gene Expression Signatures. <i>PLoS Genetics</i> , 2011, 7, e1002415.	1.5	42
84	Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites. <i>Oncotarget</i> , 2016, 7, 8055-8066.	0.8	42
85	Sequential activation and production of matrix metalloproteinase-2 during breast cancer progression. <i>Clinical and Experimental Metastasis</i> , 1996, 14, 512-519.	1.7	41
86	Adenocarcinoma of the small bowel at a single Korean institute: management and prognosticators. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 387-394.	1.2	41
87	Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. <i>Future Oncology</i> , 2019, 15, 929-941.	1.1	40
88	Stable Symptom Clusters and Evolving Symptom Networks in Relation to Chemotherapy Cycles. <i>Journal of Pain and Symptom Management</i> , 2021, 61, 544-554.	0.6	40
89	Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide. <i>Investigational New Drugs</i> , 2013, 31, 1602-1608.	1.2	39
90	Clinical Value of Ezrin Expression in Primary Osteosarcoma. <i>Cancer Research and Treatment</i> , 2009, 41, 138.	1.3	39

#	ARTICLE	IF	CITATIONS
91	Sequential production and activation of matrix-metalloproteinase-9 (MMP-9) with breast cancer progression. <i>Breast Cancer Research and Treatment</i> , 1997, 43, 175-181.	1.1	38
92	P-glycoprotein: The intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 1997, 42, 65-72.	1.1	38
93	Molecular basis of the differences between normal and tumor tissues of gastric cancer. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2007, 1772, 1033-1040.	1.8	38
94	Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors. <i>Supportive Care in Cancer</i> , 2013, 21, 1751-1759.	1.0	38
95	Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer. <i>Molecular Therapy - Oncolytics</i> , 2020, 18, 587-601.	2.0	38
96	Prevalence and associated factors of psychological distress among Korean cancer patients. <i>General Hospital Psychiatry</i> , 2011, 33, 246-252.	1.2	37
97	Characterizing the outcomes of metastatic papillary renal cell carcinoma. <i>Cancer Medicine</i> , 2017, 6, 902-909.	1.3	37
98	A Prognostic Model to Predict Clinical Outcome in Gastric Cancer Patients with Bone Metastasis. <i>Oncology</i> , 2011, 80, 142-150.	0.9	36
99	Pain Palliation in Patients with Bone Metastases Using Magnetic Resonance-Guided Focused Ultrasound with Conformal Bone System: A Preliminary Report. <i>Yonsei Medical Journal</i> , 2015, 56, 503.	0.9	36
100	Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer. <i>BMC Cancer</i> , 2013, 13, 394.	1.1	35
101	The Effect of Disintegrin-Metalloproteinase ADAM9 in Gastric Cancer Progression. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 3074-3085.	1.9	35
102	Green Tea Consumption and Stomach Cancer Risk: A Meta-Analysis. <i>Epidemiology and Health</i> , 2010, 32, e2010001.	0.8	34
103	Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients. <i>Cancer Letters</i> , 2010, 288, 124-132.	3.2	34
104	PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer. <i>Oncotarget</i> , 2017, 8, 113494-113501.	0.8	34
105	First data for sotorasib in patients with pancreatic cancer with <i>KRAS</i> p.G12C mutation: A phase I/II study evaluating efficacy and safety. <i>Journal of Clinical Oncology</i> , 2022, 40, 360490-360490.	0.8	34
106	Multi-Institutional Phase II Study of S-1 Monotherapy in Advanced Gastric Cancer with Pharmacokinetic and Pharmacogenomic Evaluations. <i>Oncologist</i> , 2007, 12, 543-554.	1.9	33
107	Bilateral Breast Cancer: Differential Diagnosis Using Histological and Biological Parameters. <i>Japanese Journal of Clinical Oncology</i> , 2007, 37, 487-492.	0.6	33
108	Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. <i>Experimental and Therapeutic Medicine</i> , 2011, 2, 685-693.	0.8	33

#	ARTICLE	IF	CITATIONS
109	Differential expression patterns of MMPs and their role in the invasion of epithelial premalignant tumors and invasive cutaneous squamous cell carcinoma. <i>Experimental and Molecular Pathology</i> , 2012, 92, 236-242.	0.9	32
110	Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 397-408.	1.1	32
111	The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status. <i>Gastric Cancer</i> , 2018, 21, 213-224.	2.7	32
112	Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial. <i>Journal of Hematology and Oncology</i> , 2018, 11, 69.	6.9	32
113	Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review. <i>International Journal of Oncology</i> , 2014, 44, 5-16.	1.4	31
114	Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology Oncology</i> , 2019, 2, 643-648.	2.6	31
115	Epstein-Barr virus BART1-induced NF $\kappa$ B/miR-146a/SMAD4 alterations in stomach cancer cells. <i>Oncotarget</i> , 2016, 7, 82213-82227.	0.8	31
116	Gene copy number change events at chromosome 20 and their association with recurrence in gastric cancer patients. <i>Clinical Cancer Research</i> , 2005, 11, 612-20.	3.2	31
117	Overexpression of c-ErbB-2 Protein in Gastric Cancer by Immunohistochemical Stain. <i>Oncology</i> , 1996, 53, 192-197.	0.9	30
118	Cyclic Induction of Senescence with Intermittent AZT Treatment Accelerates both Apoptosis and Telomere Loss. <i>Breast Cancer Research and Treatment</i> , 2005, 93, 227-236.	1.1	30
119	Genome-wide genetic aberrations of thymoma using cDNA microarray based comparative genomic hybridization. <i>BMC Genomics</i> , 2007, 8, 305.	1.2	30
120	Gastrointestinal Stromal Tumor of the Rectum: An Analysis of Seven Cases. <i>Surgery Today</i> , 2007, 37, 455-459.	0.7	30
121	High KLF4 level in normal tissue predicts poor survival in colorectal cancer patients. <i>World Journal of Surgical Oncology</i> , 2014, 12, 232.	0.8	30
122	Clinicopathologic Features of Metachronous or Synchronous Gastric Cancer Patients with Three or More Primary Sites. <i>Cancer Research and Treatment</i> , 2010, 42, 217.	1.3	29
123	A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 1206-1214.	2.7	28
124	Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study. <i>Cancer Research and Treatment</i> , 2018, 50, 488-494.	1.3	28
125	Angiogenic Factor Thymidine Phosphorylase Increases Cancer Cell Invasion Activity in Patients with Gastric Adenocarcinoma. <i>Molecular Cancer Research</i> , 2008, 6, 1554-1566.	1.5	27
126	Therapeutic Strategies for Well-differentiated Papillary Mesothelioma of the Peritoneum. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 996-1003.	0.6	27

#	ARTICLE	IF	CITATIONS
127	PTEN Deficiency as a Predictive Biomarker of Resistance to HER2-Targeted Therapy in Advanced Gastric Cancer. <i>Oncology</i> , 2015, 88, 76-85.	0.9	27
128	Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 1901-1913.	1.2	26
129	Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer. <i>Radiotherapy and Oncology</i> , 2010, 95, 303-307.	0.3	26
130	Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer. , 2019, 7, 268.		26
131	Effect of being overweight on postoperative morbidity and long-term surgical outcomes in proximal gastric carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 475-479.	1.4	25
132	The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 517-526.	1.2	25
133	A Population-Based Overview of Sequences of Targeted Therapy in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e127-e131.	0.9	25
134	Prognostic Model to Predict Survival Outcome for Curatively Resected Liposarcoma: A Multi-Institutional Experience. <i>Journal of Cancer</i> , 2016, 7, 1174-1180.	1.2	25
135	Docetaxel versus Paclitaxel Combined with 5-FU and Leucovorin in Advanced Gastric Cancer: Combined Analysis of Two Phase II Trials. <i>Cancer Research and Treatment</i> , 2009, 41, 196.	1.3	25
136	Molecular characterization of alternative SET-NUP214 fusion transcripts in a case of acute undifferentiated leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2010, 201, 73-80.	1.0	24
137	Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). <i>Gastric Cancer</i> , 2018, 21, 819-830.	2.7	24
138	Forty-nine gastric cancer cell lines with integrative genomic profiling for development of MET inhibitor. <i>International Journal of Cancer</i> , 2018, 143, 151-159.	2.3	24
139	CpG Island Methylator Phenotype and Methylation of Wnt Pathway Genes Together Predict Survival in Patients with Colorectal Cancer. <i>Yonsei Medical Journal</i> , 2018, 59, 588.	0.9	24
140	Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab, Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Oncology, 2020, 38, 3081-3081.	0.8	24
141	Synchronous elevation of soluble intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) correlates with gastric cancer progression. <i>Yonsei Medical Journal</i> , 1998, 39, 27.	0.9	23
142	Correlation of tissue and blood plasminogen activation system in breast cancer. <i>Cancer Letters</i> , 2000, 150, 137-145.	3.2	23
143	Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 797-805.	1.1	23
144	EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI. <i>Yonsei Medical Journal</i> , 2012, 53, 1128.	0.9	23

#	ARTICLE	IF	CITATIONS
145	Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition. <i>Gut</i> , 2022, 71, 1277-1288.	6.1	23
146	Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer. <i>World Journal of Gastroenterology</i> , 2015, 21, 2711.	1.4	23
147	Determination of genes related to gastrointestinal tract origin cancer cells using a cDNA microarray. <i>Clinical Cancer Research</i> , 2005, 11, 79-86.	3.2	23
148	Cyclooxygenase-2 Expression in Pretreatment Biopsy as a Predictor of Tumor Responses After Preoperative Chemoradiation in Rectal Cancer. <i>Archives of Surgery</i> , 2008, 143, 1091.	2.3	22
149	Chemokine growth-regulated oncogene 1 as a putative biomarker for gastric cancer progression. <i>Cancer Science</i> , 2010, 101, 2200-2206.	1.7	22
150	Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 635-642.	1.1	22
151	Comparison of Melanoma Subtypes among Korean Patients by Morphologic Features and Ultraviolet Exposure. <i>Annals of Dermatology</i> , 2014, 26, 485.	0.3	22
152	Angiogenic factor thymidine phosphorylase associates with angiogenesis and lymphangiogenesis in the intestinal-type gastric cancer. <i>Pathology</i> , 2014, 46, 316-324.	0.3	22
153	Regulation of the epithelial to mesenchymal transition and metastasis by Raf kinase inhibitory protein-dependent Notch1 activity. <i>Oncotarget</i> , 2016, 7, 4632-4646.	0.8	22
154	A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. <i>Investigational New Drugs</i> , 2010, 28, 650-658.	1.2	21
155	Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea. <i>BMC Cancer</i> , 2012, 12, 322.	1.1	20
156	A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. <i>Investigational New Drugs</i> , 2012, 30, 672-680.	1.2	20
157	Estimating the adjuvant chemotherapy effect in elderly stage II and III colon cancer patients in an observational study. <i>Journal of Surgical Oncology</i> , 2013, 107, 613-618.	0.8	20
158	Difference of interferon- $\gamma$ and interferon- $\beta$ on melanoma growth and lymph node metastasis in mice. <i>Melanoma Research</i> , 2013, 23, 114-124.	0.6	20
159	Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept $\alpha$ -Trial. <i>Clinical Cancer Research</i> , 2018, 24, 5272-5281.	3.2	20
160	Stability of symptom clusters and sentinel symptoms during the first two cycles of adjuvant chemotherapy. <i>Supportive Care in Cancer</i> , 2019, 27, 1687-1695.	1.0	20
161	Characteristics and Treatment Patterns of Patients with Advanced Soft Tissue Sarcoma in Korea. <i>Cancer Research and Treatment</i> , 2019, 51, 1380-1391.	1.3	20
162	Relationship between p53 Overexpression and Gastric Cancer Progression. <i>Oncology</i> , 1997, 54, 166-170.	0.9	19

#	ARTICLE	IF	CITATIONS
163	A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology. <i>Cancer Research and Treatment</i> , 2016, 48, 553-560.	1.3	19
164	Renal Cell Carcinoma Is Abrogated by p53 Stabilization through Transglutaminase 2 Inhibition. <i>Cancers</i> , 2018, 10, 455.	1.7	19
165	Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 1153-1163.	2.7	19
166	Unmet needs in the physical and daily living domain mediates the influence of symptom experience on the quality of life of gastric cancer patients. <i>Supportive Care in Cancer</i> , 2020, 28, 1419-1431.	1.0	19
167	Changes of Telomerase Activity by Alternative Splicing of Full-Length and $\hat{1}^2$ Variants of hTERT in Breast Cancer Patients. <i>Oncology Research</i> , 2009, 18, 213-220.	0.6	19
168	A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 315-321.	1.1	18
169	Efficacy of Oxaliplatin-Based Chemotherapy in Curatively Resected Colorectal Cancer with Liver Metastasis. <i>Oncology</i> , 2011, 81, 175-183.	0.9	18
170	A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf treated with chemotherapy. <i>Investigational New Drugs</i> , 2012, 30, 1501-1510.	1.2	18
171	Application of the Adjuvant! Online Model to Korean Breast Cancer Patients: An Assessment of Prognostic Accuracy and Development of an Alternative Prognostic Tool. <i>Annals of Surgical Oncology</i> , 2013, 20, 2615-2624.	0.7	18
172	Defining the target volume for post-operative radiotherapy after D2 dissection in gastric cancer by CT-based vessel-guided delineation. <i>Radiotherapy and Oncology</i> , 2013, 108, 72-77.	0.3	18
173	The Impact of Cigarette Smoking on the Frequency of and Qualitative Differences in KRAS Mutations in Korean Patients with Lung Adenocarcinoma. <i>Yonsei Medical Journal</i> , 2013, 54, 865.	0.9	18
174	Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency. <i>European Journal of Cancer</i> , 2014, 50, 746-752.	1.3	18
175	Ifosfamide-induced Fanconi syndrome with diabetes insipidus. <i>Korean Journal of Internal Medicine</i> , 2014, 29, 246.	0.7	18
176	Prognosis of pN3 Stage Gastric Cancer. <i>Cancer Research and Treatment</i> , 2009, 41, 73.	1.3	18
177	BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3164.	1.8	17
178	S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial. <i>Cancer Research and Treatment</i> , 2019, 51, 1-11.	1.3	17
179	Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations. <i>Investigational New Drugs</i> , 2021, 39, 1366-1374.	1.2	17
180	Comparison of biological phenotypes according to midkine expression in gastric cancer cells and their autocrine activities could be modulated by pentosan polysulfate. <i>Cancer Letters</i> , 1997, 118, 37-46.	3.2	16

#	ARTICLE	IF	CITATIONS
181	Induction of cell apoptosis in non-small cell lung cancer cells by cyclin A1 small interfering RNA. <i>Cancer Science</i> , 2006, 97, 1082-1092.	1.7	16
182	In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer. <i>Genomics</i> , 2009, 93, 52-61.	1.3	16
183	Genome-wide molecular characterization of mucinous colorectal adenocarcinoma using cDNA microarray analysis. <i>Oncology Reports</i> , 2011, 25, 717-27.	1.2	16
184	Safety of Everolimus by Treatment Duration in Patients With Advanced Renal Cell Cancer in an Expanded Access Program. <i>Urology</i> , 2013, 81, 143-149.	0.5	16
185	Rho GTPase RhoJ is Associated with Gastric Cancer Progression and Metastasis. <i>Journal of Cancer</i> , 2016, 7, 1550-1556.	1.2	16
186	Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma. <i>Annals of Nuclear Medicine</i> , 2016, 30, 279-286.	1.2	16
187	Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer. <i>Oncotarget</i> , 2017, 8, 61837-61845.	0.8	16
188	Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma. <i>BMC Cancer</i> , 2018, 18, 158.	1.1	16
189	The clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 113-122.	2.7	16
190	Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis. <i>European Journal of Cancer</i> , 2021, 144, 49-60.	1.3	16
191	Guidelines for Cancer Care during the COVID-19 Pandemic in South Korea. <i>Cancer Research and Treatment</i> , 2021, 53, 323-329.	1.3	16
192	Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm. <i>Oncotarget</i> , 2016, 7, 72099-72112.	0.8	16
193	Wernicke's Encephalopathy in Advanced Gastric Cancer. <i>Cancer Research and Treatment</i> , 2010, 42, 77.	1.3	16
194	Clinical Features and Treatment of Collecting Duct Carcinoma of the Kidney from the Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee. <i>Cancer Research and Treatment</i> , 2014, 46, 141-147.	1.3	16
195	Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 1998, 49, 41-50.	1.1	15
196	Lack of Correlation Between P-glycoprotein and Chemotherapy Resistance in Nasal NK/T-cell Lymphomas. <i>Leukemia and Lymphoma</i> , 2004, 45, 1857-1864.	0.6	15
197	A Phase II Study of Infusional 5-Fluorouracil and Low-Dose Leucovorin with Docetaxel for Advanced Gastric Cancer. <i>Oncology</i> , 2006, 70, 63-70.	0.9	15
198	Clinical Role of Bone Marrow Angiogenesis in Childhood Acute Lymphocytic Leukemia. <i>Yonsei Medical Journal</i> , 2007, 48, 171.	0.9	15

#	ARTICLE	IF	CITATIONS
199	Clinicopathological Features and Prognostic Significance of HER2 Expression in Gastric Cancer. <i>Oncology</i> , 2015, 88, 147-156.	0.9	15
200	Different subtypes of epithelioid sarcoma and their clinical implication: long-term multi-institutional experience with a rare sarcoma. <i>Apmis</i> , 2017, 125, 223-229.	0.9	15
201	Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer. <i>Anticancer Research</i> , 2018, 38, 6171-6180.	0.5	15
202	Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer. <i>Oncologist</i> , 2019, 24, e1108-e1114.	1.9	15
203	Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 581-581.	0.8	15
204	Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy. <i>PLoS ONE</i> , 2012, 7, e45127.	1.1	15
205	Improving the prediction accuracy in classification using the combined data sets by ranks of gene expressions. <i>BMC Bioinformatics</i> , 2008, 9, 283.	1.2	14
206	Subtelomeric DNA methylation and telomere length in human cancer cells. <i>Cancer Letters</i> , 2009, 281, 82-91.	3.2	14
207	Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer. <i>Anti-Cancer Drugs</i> , 2011, 22, 801-810.	0.7	14
208	Advanced Detection of Recent Changing Trends in Gastric Cancer Survival: Up-to-date Comparison by Period Analysis. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 1344-1350.	0.6	14
209	Pharmacogenomic Assessment of Outcomes of Pemetrexed-Treated Patients with Adenocarcinoma of the Lung. <i>Yonsei Medical Journal</i> , 2013, 54, 854.	0.9	14
210	Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study. <i>Journal of Clinical Pathology</i> , 2014, 67, 33-39.	1.0	14
211	Controlling chemotherapy-induced nausea requires further improvement: symptom experience and risk factors among Korean patients. <i>Supportive Care in Cancer</i> , 2016, 24, 3379-3389.	1.0	14
212	Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma. <i>Oncology</i> , 2019, 96, 59-69.	0.9	14
213	Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma. <i>Oncologist</i> , 2021, 26, e1704-e1729.	1.9	14
214	Weekly Gemcitabine and Docetaxel in Refractory Soft Tissue Sarcoma: A Retrospective Analysis. <i>Cancer Research and Treatment</i> , 2012, 44, 43-49.	1.3	14
215	Behaviors and Attitudes toward the Use of Complementary and Alternative Medicine among Korean Cancer Patients. <i>Cancer Research and Treatment</i> , 2019, 51, 851-860.	1.3	14
216	Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial. <i>European Urology</i> , 2022, 82, 283-292.	0.9	14

#	ARTICLE	IF	CITATIONS
217	Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 157-165.	1.1	13
218	G-T haplotype (2677G>T/A and 3435C>T) of ABCB1 gene polymorphisms is associated with ethnic differences to paclitaxel sensitivity in cancer cells with different gene expression pattern. <i>Cancer Letters</i> , 2009, 277, 155-163.	3.2	13
219	The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 3938-3945.	0.7	13
220	Recursive partition analysis of peritoneal and systemic recurrence in patients with gastric cancer who underwent D2 gastrectomy: Implications for neoadjuvant therapy consideration. <i>Journal of Surgical Oncology</i> , 2016, 114, 859-864.	0.8	13
221	A novel <i>TP53-KPNA3</i> translocation defines a de novo treatment-resistant clone in osteosarcoma. <i>Journal of Physical Education and Sports Management</i> , 2016, 2, a000992.	0.5	13
222	A Comparative Study of Intravenous Granisetron Versus Intravenous and Oral Ondansetron in the Prevention of Nausea and Vomiting Associated with Moderately Emetogenic Chemotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1997, 20, 569-572.	0.6	13
223	Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab. <i>Oncotarget</i> , 2017, 8, 31169-31179.	0.8	13
224	Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children. <i>Cancer Research and Treatment</i> , 1970, 47, 9-17.	1.3	12
225	Fibroblast Growth Factor Receptor 1 Overexpression Is Associated with Poor Survival in Patients with Resected Muscle Invasive Urothelial Carcinoma. <i>Yonsei Medical Journal</i> , 2016, 57, 831.	0.9	12
226	High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 2051-2059.	1.2	12
227	SFRP4 drives invasion in gastric cancer and is an early predictor of recurrence. <i>Gastric Cancer</i> , 2021, 24, 589-601.	2.7	12
228	Retrospective Comparison of Infusional 5-Fluorouracil, Doxorubicin, and Mitomycin-C (Modified FAM) Combination Chemotherapy Versus Palliative Therapy in Treatment of Advanced Gastric Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1997, 20, 484-489.	0.6	12
229	Phase I study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 3590-3590.	0.8	12
230	Significance of Metabolic Tumor Volume and Total Lesion Glycolysis Measured Using <sup>18</sup> F-FDG PET/CT in Locally Advanced and Metastatic Gallbladder Carcinoma. <i>Yonsei Medical Journal</i> , 2019, 60, 604.	0.9	12
231	Genetic Alterations among Korean Melanoma Patients Showing Tumor Heterogeneity: A Comparison between Primary Tumors and Corresponding Metastatic Lesions. <i>Cancer Research and Treatment</i> , 2018, 50, 1378-1387.	1.3	12
232	Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients. <i>Cancer Research and Treatment</i> , 2019, 51, 211-222.	1.3	12
233	Abstract P2-13-07: Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): Results from a phase 1 study. <i>Cancer Research</i> , 2022, 82, P2-13-07-P2-13-07.	0.4	12
234	Comparison of Long-Term Outcome between Doublet and Triplet Neoadjuvant Chemotherapy in Non-Metastatic Osteosarcoma of the Extremity. <i>Oncology</i> , 2011, 80, 107-117.	0.9	11

#	ARTICLE	IF	CITATIONS
235	Body fluid MMP-2 as a putative biomarker in metastatic breast cancer. <i>Oncology Letters</i> , 2012, 3, 699-703.	0.8	11
236	Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent. <i>Investigational New Drugs</i> , 2013, 31, 1-13.	1.2	11
237	Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer. <i>Journal of Radiation Research</i> , 2013, 54, 52-60.	0.8	11
238	<i>PINCH2</i> presents functional copy number variation and suppresses migration of colon cancer cells by paracrine activity. <i>International Journal of Cancer</i> , 2015, 136, 2273-2283.	2.3	11
239	Craniofacial osteosarcoma: Single institutional experience in Korea. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, e149-53.	0.7	11
240	Prognostic significance and frequency of EGFR expression and amplification in surgically resected advanced gastric cancer. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 507-516.	0.6	11
241	p16 methylation is a potential predictive marker for abemaciclib sensitivity in gastric cancer. <i>Biochemical Pharmacology</i> , 2021, 183, 114320.	2.0	11
242	INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG) – Final overall and subgroup results. <i>Journal of Clinical Oncology</i> , 2015, 33, 4003-4003.	0.8	11
243	p16 and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Cancer Research and Treatment</i> , 2016, 48, 208-215.	1.3	11
244	The Essentials of Multiomics. <i>Oncologist</i> , 2022, 27, 272-284.	1.9	11
245	Novel and simple transformation algorithm for combining microarray data sets. <i>BMC Bioinformatics</i> , 2007, 8, 218.	1.2	10
246	The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 75-81.	1.1	10
247	Variation of the 3' telomeric overhang lengths in human cells. <i>Cancer Letters</i> , 2008, 264, 107-118.	3.2	10
248	Upregulated, 7q21 amplicon candidate gene SHFM1 confers oncogenic advantage by suppressing p53 function in gastric cancer. <i>Cellular Signalling</i> , 2015, 27, 1075-1086.	1.7	10
249	Detection of asymptomatic recurrence improves survival of gastric cancer patients. <i>Cancer Medicine</i> , 2021, 10, 3249-3260.	1.3	10
250	Phase II trial of tesetaxel, an oral taxane, as second-line therapy for patients with advanced gastroesophageal cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 4077-4077.	0.8	10
251	First-in-human phase I study of BVAC-B cell therapy in HER2-positive advanced gastric cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 4534-4534.	0.8	10
252	Novel Sunitinib Strategy in Metastatic Renal Cell Carcinoma on Hemodialysis: Intermittent Dose of Sunitinib after Hemodialysis. <i>Cancer Research and Treatment</i> , 2010, 42, 180.	1.3	10

#	ARTICLE	IF	CITATIONS
253	Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine. <i>Cancer Research and Treatment</i> , 2015, 47, 781-789.	1.3	10
254	Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial. <i>Cancer Research and Treatment</i> , 2019, 51, 819-831.	1.3	10
255	Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer. <i>American Journal of Cancer Research</i> , 2015, 5, 72-86.	1.4	10
256	Systematic analysis of cDNA microarray-based CGH. <i>International Journal of Molecular Medicine</i> , 2006, 17, 261-7.	1.8	10
257	Trial in progress: Phase 3 study of bezarituzumab + mFOLFOX6 versus placebo + mFOLFOX6 in previously untreated advanced gastric or gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-101).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4164-TPS4164.	0.8	10
258	Treatment of recurrent hepatocellular carcinoma after liver transplantation. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 258-269.	0.7	9
259	Telomerase- and angiogenesis-related gene responses to irradiation in human umbilical vein endothelial cells. <i>International Journal of Molecular Medicine</i> , 2013, 31, 1202-1208.	1.8	9
260	First-Line Mammalian Target of Rapamycin Inhibition in Metastatic Renal Cell Carcinoma: An Analysis of Practice Patterns From the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 335-340.	0.9	9
261	Low concentration vemurafenib induces the proliferation and invasion of human HaCaT keratinocytes through mitogen-activated protein kinase pathway activation. <i>Journal of Dermatology</i> , 2015, 42, 881-888.	0.6	9
262	Leiomyosarcoma: investigation of prognostic factors for risk-stratification model. <i>International Journal of Clinical Oncology</i> , 2015, 20, 1226-1232.	1.0	9
263	Modulation of HAT activity by the BRCA2 N372H variation is a novel mechanism of paclitaxel resistance in breast cancer cell lines. <i>Biochemical Pharmacology</i> , 2017, 138, 163-173.	2.0	9
264	RNA Editing Signature to Guide Gastric Cancer Chemotherapy. <i>Cancer Research</i> , 2021, 81, 2788-2798.	0.4	9
265	Cytoreductive nephrectomy (CN) in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 396-396.	0.8	9
266	Synergistic Antitumor Effects of Combined Treatment with HSP90 Inhibitor and PI3K/mTOR Dual Inhibitor in Cisplatin-Resistant Human Bladder Cancer Cells. <i>Yonsei Medical Journal</i> , 2020, 61, 587.	0.9	9
267	Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 383-390.	0.7	9
268	An Attempt for Combining Microarray Data Sets by Adjusting Gene Expressions. <i>Cancer Research and Treatment</i> , 2007, 39, 74.	1.3	9
269	A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 59, 313-320.	1.1	8
270	Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer. <i>Radiotherapy and Oncology</i> , 2008, 87, 361-366.	0.3	8

#	ARTICLE	IF	CITATIONS
271	Changing treatment patterns in elderly patients with resectable colon cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2013, 9, 265-272.	0.7	8
272	Development and evaluation of the Cancer Symptom Management System: Symptom Management Improves your Life (SMILE)â€”a randomized controlled trial. <i>Supportive Care in Cancer</i> , 2020, 28, 713-723.	1.0	8
273	A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4510-4510.	0.8	8
274	Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer. <i>Oncotarget</i> , 2017, 8, 38389-38398.	0.8	8
275	A weighted sample size for microarray datasets that considers the variability of variance and multiplicity. <i>Journal of Bioscience and Bioengineering</i> , 2009, 108, 252-258.	1.1	7
276	Increments of Î±1â€”dystroglycan expression in liver metastasis correlate with poor survival in gastric cancer. <i>Journal of Surgical Oncology</i> , 2009, 100, 459-465.	0.8	7
277	A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIb-IV (M0) gastric cancer. <i>Investigational New Drugs</i> , 2012, 30, 357-363.	1.2	7
278	Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 799-808.	1.1	7
279	Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11. <i>Gastric Cancer</i> , 2018, 21, 802-810.	2.7	7
280	Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancer. <i>Radiotherapy and Oncology</i> , 2019, 140, 143-149.	0.3	7
281	Antibody-Based Targeting of Interferon-Beta-1a Mutein in HER2-Positive Cancer Enhances Antitumor Effects Through Immune Responses and Direct Cell Killing. <i>Frontiers in Pharmacology</i> , 2020, 11, 608774.	1.6	7
282	The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT).. <i>Journal of Clinical Oncology</i> , 2014, 32, 398-398.	0.8	7
283	INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)â€”A study by the Australasian Gastrointestinal Trials Group (AGITG), first results.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9-9.	0.8	7
284	Prognostic implications of <i>PIK3CA</i> amplification in curatively resected liposarcoma. <i>Oncotarget</i> , 2016, 7, 24549-24558.	0.8	7
285	Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. <i>Cancer Letters</i> , 2008, 270, 269-276.	3.2	6
286	A Phase II Feasibility Study of Weekly Paclitaxel in Heavily Pretreated Advanced Gastric Cancer Patients with Poor Performance Status. <i>Oncology</i> , 2009, 77, 349-357.	0.9	6
287	Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 919-927.	1.1	6
288	Systematic Analyses of Genes Associated with Radiosensitizing Effect by Celecoxib, a Specific Cyclooxygenase-2 Inhibitor. <i>Journal of Radiation Research</i> , 2011, 52, 752-765.	0.8	6

#	ARTICLE	IF	CITATIONS
289	<i>PTEN</i> Methylation Dependent Sinonasal Mucosal Melanoma. Cancer Research and Treatment, 2016, 48, 853-858.	1.3	6
290	Assessment of Adrenal Function and Health-Related Quality of Life in Advanced Gastric Cancer Patients Who Received First-Line Chemotherapy. Oncology, 2016, 90, 248-254.	0.9	6
291	Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer. Oncology Letters, 2017, 14, 2385-2392.	0.8	6
292	Regulation of proliferation and invasion by the <sc>IGF</sc> signalling pathway in Epstein-Barr virus-positive gastric cancer. Journal of Cellular and Molecular Medicine, 2018, 22, 5899-5908.	1.6	6
293	Scale-Up Evaluation of a Composite Tumor Marker Assay for the Early Detection of Renal Cell Carcinoma. Diagnostics, 2020, 10, 750.	1.3	6
294	Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16). Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110428.	1.4	6
295	Clinical pattern and implication of PD-L1 expression in soft-tissue sarcoma.. Journal of Clinical Oncology, 2015, 33, 10565-10565.	0.8	6
296	Prognostic significance of "inflamed" gene expression profile and PD-L1 expression in patients with esophageal cancer. Cancer Medicine, 2021, 10, 8365-8376.	1.3	6
297	Telomerase reverse transcriptase (TERT) promoter mutations in Korean melanoma patients. American Journal of Cancer Research, 2017, 7, 134-138.	1.4	6
298	Self-efficacy for coping with cancer and quality of life in advanced gastric cancer patients. European Journal of Oncology Nursing, 2022, 58, 102120.	0.9	6
299	Safety and clinical activity of MEDI5752, a PD-1/CTLA-4 bispecific checkpoint inhibitor, as monotherapy in patients (pts) with advanced renal cell carcinoma (RCC): Preliminary results from an FTIH trial.. Journal of Clinical Oncology, 2022, 40, 107-107.	0.8	6
300	A new prognostic index model using meta-analysis in early-stage epithelial ovarian cancer. Gynecologic Oncology, 2012, 126, 357-363.	0.6	5
301	Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma. Cancer Chemotherapy and Pharmacology, 2013, 72, 853-860.	1.1	5
302	Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC).. Journal of Clinical Oncology, 2015, 33, 4554-4554.	0.8	5
303	Safety and preliminary antitumor activity of the transforming growth factor beta (TGF- $\beta$ ) receptor I kinase inhibitor, vactosertib, in combination with paclitaxel in patients with metastatic gastric adenocarcinoma.. Journal of Clinical Oncology, 2020, 38, e16505-e16505.	0.8	5
304	Efficacy and Toxicity of Mammalian Target Rapamycin Inhibitors in Patients with Metastatic Renal Cell Carcinoma with Renal Insufficiency: The Korean Cancer Study Group GU 14-08. Cancer Research and Treatment, 2016, 48, 1286-1292.	1.3	5
305	Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma. Cancer Research and Treatment, 2019, 51, 1578-1588.	1.3	5
306	Quantitative detection of telomerase activity by real-time TRAP assay in the body fluids of cancer patients. International Journal of Molecular Medicine, 2005, 16, 857-63.	1.8	5

#	ARTICLE	IF	CITATIONS
307	Phase II Clinical Trial of Eribulin+Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 3225-3234.	3.2	5
308	The first report of K-Umbrella Gastric Cancer Study: An open label, multi-center, randomized, biomarker-integrated trial for second-line treatment of advanced gastric cancer (AGC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 4001-4001.	0.8	5
309	Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 991-999.	1.1	4
310	PIK3CA Mutations in Hepatocellular Carcinoma in Korea. <i>Yonsei Medical Journal</i> , 2013, 54, 883.	0.9	4
311	Kaposi's Varicelliform-Like Eruption in a Patient Treated with Everolimus for Metastatic Renal Cell Carcinoma: Report of a Rare Case. <i>Case Reports in Oncology</i> , 2014, 7, 337-342.	0.3	4
312	Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10. <i>Gynecologic Oncology</i> , 2015, 136, 212-217.	0.6	4
313	Gaps exist between patients's experience and clinicians's awareness of symptoms after chemotherapy: CINV and accompanying symptoms. <i>Supportive Care in Cancer</i> , 2016, 24, 4559-4566.	1.0	4
314	A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 773-781.	1.2	4
315	Development and validation of a targeted sequencing panel for application to treatment-refractory solid tumor.. <i>Journal of Clinical Oncology</i> , 2021, 39, 245-245.	0.8	4
316	The impact of body mass index (BMI) on treatment outcome of targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Cancer Database Consortium.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4576-4576.	0.8	4
317	Microarray-based tumor molecular profiling to direct choice of cisplatin plus S-1 or oxaliplatin plus S-1 for advanced gastric cancer: A multicentre, prospective, proof-of-concept phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 48-48.	0.8	4
318	A Locally Advanced Breast Cancer with Difficult Differential Diagnosis of Carcinosarcoma and Atypical Medullary Carcinoma, which had Poor Response to Adriamycin- and Taxane-based Neoadjuvant Chemotherapy: A Case Report. <i>Cancer Research and Treatment</i> , 2007, 39, 134.	1.3	4
319	Methylation Status of Lamin A/C in Gastric Cancer Cell Lines. <i>Hepato-Gastroenterology</i> , 2012, 59, 1313-8.	0.5	4
320	An in-depth multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) that do not meet eligibility criteria for clinical trials.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4536-4536.	0.8	4
321	An unusual case of gastric carcinoma with synchronous non-Hodgkin's lymphoma. <i>Yonsei Medical Journal</i> , 1998, 39, 463.	0.9	3
322	Benefits of Recurrent Colonic Stent Insertion in a Patient with Advanced Gastric Cancer with Carcinomatosis Causing Colonic Obstruction. <i>Yonsei Medical Journal</i> , 2009, 50, 296.	0.9	3
323	Identification of significant regional genetic variations using continuous CNV values in aCGH data. <i>Genomics</i> , 2009, 94, 317-323.	1.3	3
324	A Phase II Study of a Combined Biweekly Irinotecan and Monthly Cisplatin Treatment for Metastatic or Recurrent Gastric Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 56-60.	0.6	3

#	ARTICLE	IF	CITATIONS
325	ABCB1 2677G>T/A variant enhances chemosensitivity to anti-cancer agents acting on microtubule dynamics through LAMP1 inhibition. <i>Biochemical Pharmacology</i> , 2017, 123, 73-84.	2.0	3
326	A phase IB study of CX-4945 in combination with gemcitabine plus cisplatin in the frontline systemic treatment of patients with advanced cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 294-294.	0.8	3
327	Institutional Board Review for Clinical Investigations on Inflammatory Bowel Diseases: A Single-Center Study. <i>Intestinal Research</i> , 2015, 13, 274.	1.0	3
328	T-cellâ€inflamed gene expression profile (GEP) and PD-L1 expression in patients (pts) with esophageal cancer (EC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 26-26.	0.8	3
329	Transcriptome analysis of iBET-151, a BET inhibitor alone and in combination with paclitaxel in gastric cancer cells. <i>Genomics and Informatics</i> , 2020, 18, e37.	0.4	3
330	Inhibition of the bromodomain and extra-terminal family of epigenetic regulators as a promising therapeutic approach for gastric cancer. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 1387-1403.	2.1	3
331	Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16). <i>Gastric Cancer</i> , 2022, 25, 609-618.	2.7	3
332	Fear of cancer recurrence and its predictors and outcomes among cancer survivors: A descriptive correlational study. <i>European Journal of Oncology Nursing</i> , 2022, 58, 102138.	0.9	3
333	Different criteria for HER2 positivity by IHC can be applied in post-chemotherapy specimens in determining HER2 as a prognosticator in locally advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2007, 104, 31-37.	1.1	2
334	Prediction of high-risk patients by genome-wide copy number alterations from remaining cancer after neoadjuvant chemotherapy and surgery. <i>International Journal of Oncology</i> , 2009, 34, 837-46.	1.4	2
335	Two Dosages of Oral Fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: Comparison of the Pharmacokinetic Profiles in Korean Patients with Advanced Gastric Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 29-35.	0.6	2
336	A Case of Gingival Candidiasis with Bone Destruction on Gastric Cancer Patient Receiving Cytotoxic Chemotherapy. <i>Case Reports in Oncological Medicine</i> , 2014, 2014, 1-5.	0.2	2
337	Prevalence of human papillomavirus infection and <scp>RAS</scp> mutation in sporadic keratoacanthoma. <i>International Journal of Dermatology</i> , 2015, 54, e453-7.	0.5	2
338	â€Screening auditâ€™™ as a quality assurance tool in good clinical practice compliant research environments. <i>BMC Medical Ethics</i> , 2018, 19, 30.	1.0	2
339	Reconsideration of sample size and power calculation for overall survival in cancer clinical trials. <i>Contemporary Clinical Trials Communications</i> , 2018, 12, 90-91.	0.5	2
340	Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer. <i>European Journal of Cancer</i> , 2019, 112, 20-28.	1.3	2
341	A serum microRNA biomarker panel for detection of gastric cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4060-4060.	0.8	2
342	A phase 2 trial of lenvatinib 18 mg versus 14 mg once daily (QD) in combination with everolimus (5 mg) Tj ETQq0 0 0 rgBT /Overlock 10 <i>Oncology</i> , 2018, 36, TPS707-TPS707.	0.8	2

#	ARTICLE	IF	CITATIONS
343	PD-L1 expression and overall survival in Asian and western patients with gastric cancer. <i>Future Oncology</i> , 2022, 18, 2623-2634.	1.1	2
344	Statistical Issues in the Search for Biomarkers of Colorectal Cancer Using Microarray Experiments. <i>Wiley Series in Probability and Statistics</i> , 2006, , 333-343.	0.0	1
345	Cetuximab rescue a patient with non-small cell lung cancer from rapid disease progression during chemotherapy. <i>Acta Oncologica</i> , 2007, 46, 547-549.	0.8	1
346	Copy number changes can be a predictor for hemoglobin reduction after S-1 monotherapy in gastric cancer. <i>International Journal of Oncology</i> , 2009, 34, 787-96.	1.4	1
347	Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience. <i>BMC Cancer</i> , 2012, 12, 471.	1.1	1
348	Gene Expression Profiling Identifies Akt as a Target for Radiosensitization in Gastric Cancer Cells. <i>Frontiers in Oncology</i> , 2020, 10, 562284.	1.3	1
349	Eribulin and gemcitabine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A multicenter, single-arm, phase 2-trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11516-11516.	0.8	1
350	Value of cabozantinib in the treatment of advanced metastatic clear cell renal cell carcinoma (ccRCC): Real-world data from a single Korean institution.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16578-e16578.	0.8	1
351	Real-world outcomes of second-line ramucirumab plus paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A nationwide retrospective study in Korea (KCSG-ST19-16).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4056-4056.	0.8	1
352	Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer (HER-RAM study).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4063-4063.	0.8	1
353	Abstract 945: Trastuzumab deruxtecan (T-DXd) sensitivity in various levels of HER2 expressing gastric cancer cells. , 2021, , .		1
354	Vascular endothelial growth factor (VEGF) therapy in metastatic renal cell carcinoma (mRCC): Differences between Asian and non-Asian patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, 451-451.	0.8	1
355	Biomarker analysis from a phase III trial (GOLD) of dovitinib (Dov) versus sorafenib (Sor) in patients with metastatic renal cell carcinoma after one prior VEGF pathway-targeted therapy and one prior mTOR inhibitor therapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 473-473.	0.8	1
356	Risk factors and a model to predict toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: Results from the International Metastatic RCC Database Consortium.. <i>Journal of Clinical Oncology</i> , 2015, 33, 464-464.	0.8	1
357	Prospective validation of a serum miRNA panel for early detection of gastric cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4065-4065.	0.8	1
358	Long-term Survival after Surgical Resection for Liver Metastasis from Gastric Cancer: Two Case Reports. <i>Cancer Research and Treatment</i> , 2006, 38, 184.	1.3	1
359	Safety and efficacy of everolimus in Asian patients with metastatic renal cell carcinoma (mRCC) who failed previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI) therapy: A subanalysis of REACT.. <i>Journal of Clinical Oncology</i> , 2012, 30, e15064-e15064.	0.8	1
360	Discontinuing VEGF-targeted therapy (VEGF-TT) for progression versus toxicity impacts outcomes of second-line therapies in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 503-503.	0.8	1

#	ARTICLE	IF	CITATIONS
361	PD-L1 expression in patients with metastatic gastric cancer in South Korea.. Journal of Clinical Oncology, 2017, 35, 1571-1571.	0.8	1
362	An open-label, phase I trial of BI 754091 alone and in combination with BI 754111 in Asian patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2020, 38, 3054-3054.	0.8	1
363	An open-label, multicenter, phase II study of ceritinib in patients with advanced ALK+ non-lung solid tumors and hematological malignancies (ASCEND-10).. Journal of Clinical Oncology, 2020, 38, 3520-3520.	0.8	1
364	Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: Updated HER-RAM study with biomarker analysis.. Journal of Clinical Oncology, 2022, 40, 330-330.	0.8	1
365	Biological phenotype determination with ex vivo model in gastric cancer for matrix-metalloproteinase inhibitor treatment. International Journal of Molecular Medicine, 2002, 10, 251-6.	1.8	1
366	Vascular Soft-Tissue Sarcomas: A Prognostic Model from a Retrospective Single-Center Study. Oncology, 2014, 86, 329-335.	0.9	0
367	Current Strategy of Chemotherapy for Bone Tumors. The Journal of the Korean Orthopaedic Association, 2015, 50, 438.	0.0	0
368	The Benefit of Pro Re Nata Antiemetics Provided With Guideline-Consistent Antiemetics in Delayed Nausea Control. Cancer Nursing, 2018, 41, E49-E57.	0.7	0
369	A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy. AAPS Journal, 2018, 20, 72.	2.2	0
370	Multi-omics characterization of left-right colorectal cancer.. Journal of Clinical Oncology, 2021, 39, 3542-3542.	0.8	0
371	Abstract 2055: Evaluation of DNA damage repair gene alterations, microsatellite instability status, and tumor mutational burden as predictive biomarkers of olaparib sensitivity in gastric cancer. , 2021, , .		0
372	Abstract 2973: Establishment of organoids and patient derived cancer cell lines from gastric cancer body fluids as preclinical models for personalized therapy. , 2021, , .		0
373	Clinical Implication of Bone Marrow Angiogenesis in Childhood Acute Lymphocytic Leukemia.. Blood, 2005, 106, 1455-1455.	0.6	0
374	S-1 Monotherapy as a Neoadjuvant Treatment for Locally Advanced Gastric Cancer. Korean Journal of Internal Medicine, 2008, 23, 37.	0.7	0
375	Aberrant DNA Methylation in Childhood Acute Lymphoblastic Leukemia as a Potential Biomarker Reflecting Disease Status.. Blood, 2009, 114, 2637-2637.	0.6	0
376	Comparison of S-1 and cisplatin combination versus S-1 adjuvant chemotherapy for advanced gastric cancer.. Journal of Clinical Oncology, 2012, 30, e14652-e14652.	0.8	0
377	Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma (mRCC) treated with targeted therapy: Results from the International mRCC Database Consortium.. Journal of Clinical Oncology, 2012, 30, 4538-4538.	0.8	0
378	The efficacy and toxicity of 3-weekly TS-1 containing chemotherapy in patients with unresectable advanced gastric cancer.. Journal of Clinical Oncology, 2012, 30, e14580-e14580.	0.8	0

#	ARTICLE	IF	CITATIONS
379	Efficacy and toxicity of sunitinib in renal insufficiency patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2013, 31, e15573-e15573.	0.8	0
380	A phase 2 study of trastuzumab in combination with S-1 and cisplatin in first-line human epidermal growth factor receptor (HER)-2-positive advanced gastric cancer.. Journal of Clinical Oncology, 2014, 32, 127-127.	0.8	0
381	MAPK-signaling inhibition as a genome-based precision medicine in refractory osteosarcoma.. Journal of Clinical Oncology, 2014, 32, e22164-e22164.	0.8	0
382	Everolimus-associated pneumonitis in Asian metastatic renal cell carcinoma patients.. Journal of Clinical Oncology, 2014, 32, e15596-e15596.	0.8	0
383	Do all patients with HER2-positive gastric/GEJ cancer benefit from trastuzumab?. Journal of Clinical Oncology, 2015, 33, 185-185.	0.8	0
384	Retrospective analysis of chemotherapy for the patients with advanced bladder adenocarcinoma.. Journal of Clinical Oncology, 2015, 33, 399-399.	0.8	0
385	Modeling post-progression survival in patients with HER2-positive metastatic gastric cancer.. Journal of Clinical Oncology, 2015, 33, e15020-e15020.	0.8	0
386	A phase III study to compare efficacy and safety of DHP107 (oral paclitaxel) versus IV paclitaxel in patients with metastatic or recurrent gastric cancer after failure of first-line chemotherapy (DREAM).. Journal of Clinical Oncology, 2015, 33, TPS4138-TPS4138.	0.8	0
387	Characteristics of metastatic renal cell carcinoma (mRCC) patients treated with delayed targeted therapy: Results from the International mRCC Consortium (IMDC).. Journal of Clinical Oncology, 2015, 33, 4558-4558.	0.8	0
388	Prognostic impact of different FDG-PET uptake according to histology in advanced gastric cancer.. Journal of Clinical Oncology, 2015, 33, 4113-4113.	0.8	0
389	A Prediction Model of Tumor Progression and Survival in HER2 Positive Metastatic Gastric Cancer Patients treated with Trastuzumab and Chemotherapy. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY31-2.	0.0	0
390	Real-world first-line advanced gastric cancer in western and Asian countries: Treatment patterns and impact on quality of life (QOL).. Journal of Clinical Oncology, 2018, 36, e16018-e16018.	0.8	0
391	Diagnostic accuracy of CT-staging of advanced gastric cancer following neoadjuvant chemotherapy.. Journal of Clinical Oncology, 2020, 38, 4551-4551.	0.8	0
392	Genomic profiling as a response predictor of second-line treatment in advanced gastric cancer patients: Post-hoc analyses of two phase Ib/II trials.. Journal of Clinical Oncology, 2022, 40, 351-351.	0.8	0
393	Abstract 5445: New discovery and development of transglutaminase 2 inhibitor. Cancer Research, 2022, 82, 5445-5445.	0.4	0
394	Abstract CT122: A phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel in patients with HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma and in combination with tucatinib in patients with HER2 low gastric or gastroesophageal junction (GEJ) adenocarcinoma. Cancer Research, 2022, 82, CT122-CT122.	0.4	0
395	Safety and efficacy of YBL-006, an anti-PD-1 monoclonal antibody in advanced solid tumors: A phase I study.. Journal of Clinical Oncology, 2022, 40, e14557-e14557.	0.8	0